J&J Secures EU Nod for Akeega in BRCA1/2 mHSPC After 50% Progression Risk Cut
European Commission approved J&J’s Akeega (niraparib plus abiraterone) with prednisone or prednisolone and ADT for BRCA1/2-mutated metastatic hormone-sensitive prostate cancer after phase III AMPLITUDE data showed a nearly 50% reduction in progression or death risk. Shares have rallied 35.9% over six months versus a 19.7% industry gain.
1. Expanded European Indication
European Commission approved Akeega in combination with prednisone or prednisolone plus androgen deprivation therapy to treat BRCA1/2-mutated metastatic hormone-sensitive prostate cancer, extending its indication beyond metastatic castration-resistant settings.
2. Phase III AMPLITUDE Results
The AMPLITUDE trial demonstrated that the Akeega-prednisone regimen nearly halved the risk of disease progression or death and showed an early trend toward improved overall survival compared with standard of care in BRCA-mutated mHSPC patients.
3. Regulatory Milestones and Portfolio Context
This EU approval follows a 2023 indication in metastatic castration-resistant prostate cancer and a 2025 FDA label for BRCA2-mutated castration-sensitive disease, underscoring J&J’s growing oncology franchise, which accounts for 27% of total revenues and aims for $50 billion in sales by 2030.
4. Market Reaction and Outlook
J&J shares have outperformed, rising 35.9% over the past six months versus a 19.7% industry increase, reflecting investor optimism in near-term oncology catalysts and long-term precision therapy growth.